InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K

InMed Pharmaceuticals reports 2024 executive compensation

By ExecPay News

Published: October 28, 2024

InMed Pharmaceuticals reported fiscal year 2024 executive compensation information on October 28, 2024.
In 2024, six executives at InMed Pharmaceuticals received on average a compensation package of $255K, a 5% increase compared to previous year.
Average pay of disclosed executives at InMed Pharmaceuticals
Eric A. Adams, Chief Executive Officer, received $415K in total, which increased by 13% compared to 2023. 71% of Adams' compensation, or $294K, was in salary. Adams also received $74K in bonus and $48K in option awards.
Michael Woudenberg, Chief Operating Officer, received a compensation package of $349K, which increased by 17% compared to previous year. 78% of the compensation package, or $272K, was in salary.
Eric Hsu, Senior Vice President, Preclinical Research & Development, earned $323K in 2024, a 24% increase compared to previous year.
Alexandra Mancini, Senior Vice President, Clinical & Regulatory Affairs, received $314K in 2024, which increases by 10% compared to 2023.
Netta Jagpal, Chief Financial Officer, earned $121K in 2024.
Jonathan Tegge, Chief Financial Officer, received $11K in 2024, which increases by 400% compared to 2023.
InMed Pharmaceuticals' fiscal year ends on June 30.

Related executives

Eric Adams

InMed Pharmaceuticals

Chief Executive Officer

Netta Jagpal

InMed Pharmaceuticals

Chief Financial Officer

Jonathan Tegge

InMed Pharmaceuticals

Chief Financial Officer

Michael Woudenberg

InMed Pharmaceuticals

Chief Operating Officer

Alexandra Mancini

InMed Pharmaceuticals

Senior Vice President, Clinical & Regulatory Affairs

Eric Hsu

InMed Pharmaceuticals

Senior Vice President, Preclinical Research & Development

You may also like

Source: SEC filing on October 28, 2024.